Correlation between Serum CD3+,CD4+,CD8+ T Lymphocyte Levels and the Efficacy and Prognosis of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer
Objective:To explore the correlation between serum levels of CD3+,CD4+ and CD8+ T lymphocytes and the efficacy and prognosis of concurrent chemoradiotherapy for locally advanced esophageal cancer.Method:Clinical data of 118 patients with locally advanced esophageal cancer who received concurrent chemoradiotherapy in Quanzhou Guangqian Hospital from June 2021 to June 2023 were retrospectively analyzed.According to the treatment effect,they were divided into effective group(n=93)and ineffective group(n=25).Serum levels of CD3+,CD4+ and CD8+ T lymphocytes were compared between the two groups before and after treatment.The value of serum CD3+,CD4+,CD8+ T lymphocyte levels combined with diagnostic efficacy was analyzed by receiver operating characteristic(ROC)curve.They were divided into good prognosis group(n=85)and poor prognosis group(n=33)according to the occurrence of adverse events 6 months after treatment.Baseline data and serum levels of CD3+,CD4+ and CD8+ T lymphocytes of the good prognosis group and poor prognosis group were compared,and the correlation between serum levels of CD3+,CD4+ and CD8+ T lymphocytes and prognosis was analyzed.Result:After treatment,the serum levels of CD3+,CD4+ and CD8+ T lymphocytes in the effective group were higher than those in the ineffective group,and the differences were statistically significant(P＜0.05).The AUC of serum CD3+,CD4+,and CD8+T lymphocytes combined to predict the curative effect was 0.911,which was higher than 0.827,0.743,and 0.736 of serum CD3+,CD4+,and CD8+T lymphocytes alone.Serum levels of CD3+,CD4+ and CD8+ T lymphocytes in the good prognosis group were higher than those in the poor prognosis group,and the differences were statistically significant(P＜0.05).Spearman correlation analysis showed that serum CD3+,CD4+,CD8+ T lymphocyte levels were positively correlated with the prognosis of patients with locally advanced esophageal cancer(P＜0.05).Conclusion:Serum CD3+,CD4+,CD8+ T lymphocyte levels can be used as an auxiliary index for clinical evaluation of the efficacy of concurrent chemoradiotherapy in patients with esophageal cancer,which is positively correlated with the prognosis,and can provide a reliable basis for clinical evaluation of efficacy and prognosis.
Levels of T lymphocyteLocally advanced esophageal cancerConcurrent chemoradiotherapy
国家科技期刊平台
NSTL
万方数据
